NLRP3 and liver dysplastic nodule: EA inhibits the high-mobility group Box 1 (HMGB1)/NLRP3/NF-κB pathway, and HMGB1 inhibition enhances the anti-inflammatory effect of EA on DN by suppressing the NLRP3/NF-κB pathway [57].